The EPIC study: a lesson to learn.

Area of Science:

• Haematology
• Immunology
• Paediatrics

Background:

• Inhibitory antibodies to factor VIII (FVIII) are a major complication in haemophilia A, affecting approximately 30% of previously untreated patients (PUPs).
• The precise reasons for inhibitor development in some patients remain unclear, posing a significant challenge in haemophilia A management.

Purpose of the Study:

• To test the hypothesis that early, low-dose weekly FVIII prophylaxis (25 IU kg(-1) rAHF-PFM) initiated before one year of age can reduce inhibitor incidence in PUPs.
• To minimize inhibitor development by avoiding specific immunological danger signals, including surgery, central venous access devices, and concurrent FVIII infusions with infections or vaccinations.

Main Methods:

• The Early Prophylaxis Immunologic Challenge (EPIC) study enrolled PUPs with severe or moderately severe haemophilia A.
• Participants received once-weekly FVIII prophylaxis starting before 1 year of age, with strategies to minimize immune system challenges.
• Inhibitor development was monitored, defined by plasma inhibitor activity levels.

Main Results:

• The study was terminated early due to a low likelihood of achieving the primary objective.
• Eight out of 19 (42.1%) treated subjects developed confirmed inhibitors.
• Three of the 11 PUPs without prior FVIII exposure (27.3%) developed inhibitors along with FVIII-binding antibodies.

Conclusions:

• The EPIC study's hypothesis could not be confirmed due to early termination.
• Current definitions of FVIII inhibitors based solely on activity levels (≥0.6 BU mL(-1)) may not always accurately reflect neutralizing antibody presence.
• Low-level inhibitor activity findings necessitate confirmatory testing and assessment of therapeutic response for accurate diagnosis.